When focusing on ATM, CHEK2, and PALB2, the prevalence of PVs in patients with BC/OC FH was 7.7% (18/235), whereas that in patients without BC/OC FH was 2.9% (3/102) (Fisher’s exact test, p = 0.14). This evidence concerns the gene CHEK2 and breast cancer.